Investigation on the usefulness of liquid biopsy for tumor-derived circulating DNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIs
Not Applicable
- Conditions
- on-small cell Lung Cancer
- Registration Number
- JPRN-UMIN000023248
- Lead Sponsor
- PHRF
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 122
Inclusion Criteria
Not provided
Exclusion Criteria
1)Prior treatment with EGFR-TKI 2)HBsAg or HCV-RNA positive Patients 3)HIV positive Patients
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method *The plasma DNA T790M positivity rates by Cobas EGFR Mutation Test in the T790M positive tumors patients. *The plasma DNA T790M positivity rates at each clinical point.
- Secondary Outcome Measures
Name Time Method *The plasma DNA EGFR Exon 19 deletion or Exon 21 L858 mutation positivety rates in clinical courses *Time from plasma T790 positivity to tissue T790M positivity in the tissue T790M-positive cases *Response Rate and PFS with Osimertinib *Response Rate and PFS with rechallenge of other EGFR-TKIs